Hyperpolarized 13C-Pyruvate Metabolism as a Surrogate for Tumor Grade and Poor Outcome in Renal Cell Carcinoma—A Proof of Principle Study
Authors:
- Stephan UrsprungSUStephan Ursprung
- Ramona WoitekRWRamona Woitek
- Mary A. McLeanMMMary A. McLean
- Andrew N. PriestAPAndrew N. Priest
- Mireia Crispin-OrtuzarMCMireia Crispin-Ortuzar
- Cara R. BrodieCBCara R. Brodie
- Andrew B. GillAGAndrew B. Gill
- Marcel GehrungMGMarcel Gehrung
- Lucian BeerLBLucian Beer
- Antony C. P. RiddickARAntony C. P. Riddick
- Johanna Field-RaynerJFJohanna Field-Rayner
- James T. GristJames T. Grist
Open Access
Abstract
Differentiating aggressive clear cell renal cell carcinoma (ccRCC) from indolent lesions is challenging using conventional imaging. This work prospectively compared the metabolic imaging phenotype of renal tumors using carbon-13 MRI following injection of hyperpolarized [1-13C]pyruvate (HP-13C-MRI) and validated these findings with histopathology. Nine patients with treatment-naïve renal tumors (6 ccRCCs, 1 liposarcoma, 1 pheochromocytoma, 1 oncocytoma) underwent pre-operative HP-13C-MRI and conventional proton (1H) MRI. Multi-regional tissue samples were collected using patient-specific 3D-printed tumor molds for spatial registration between imaging and molecular analysis. The apparent exchange rate constant (kPL) between 13C-pyruvate and 13C-lactate was calculated. Immunohistochemistry for the pyruvate transporter (MCT1) from 44 multi-regional samples, as well as associations between MCT1 expression and outcome in the TCGA-KIRC dataset, were investigated. Increasing kPL in ccRCC was correlated with increasing overall tumor grade (ρ = 0.92, p = 0.009) and MCT1 expression (r = 0.89, p = 0.016), with similar results acquired from the multi-regional analysis. Conventional 1H-MRI parameters did not discriminate tumor grades. The correlation between MCT1 and ccRCC grade was confirmed within a TCGA dataset (p < 0.001), where MCT1 expression was a predictor of overall and disease-free survival. In conclusion, metabolic imaging using HP-13C-MRI differentiates tumor aggressiveness in ccRCC and correlates with the expression of MCT1, a predictor of survival. HP-13C-MRI may non-invasively characterize metabolic phenotypes within renal cancer.Keywords
Funding Information
- Cancer Research UK (C19212/A16628, C19212/A911376, C19212/A27150, C9685/A25117)
- Wellcome (095962)
- Mark Foundation For Cancer Research (C9685/A25177)
- Addenbrooke's Charitable Trust, Cambridge University Hospitals (NA)
- Austrian Science Fund (J4025-B26)
This publication has 47 references indexed in Scilit:
- The International Society of Urological Pathology (ISUP) Grading System for Renal Cell Carcinoma and Other Prognostic ParametersAmerican Journal of Surgical Pathology, 2013
- Disrupting proton dynamics and energy metabolism for cancer therapyNature Reviews Cancer, 2013
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion SequencingNew England Journal of Medicine, 2012
- Genome‐wide RNA interference analysis of renal carcinoma survival regulators identifies MCT4 as a Warburg effect metabolic targetThe Journal of Pathology, 2012
- IDEAL spiral CSI for dynamic metabolic MR imaging of hyperpolarized [1‐13C]pyruvateMagnetic Resonance in Medicine, 2011
- Metastatic Potential in Renal Cell Carcinomas ≤7cm: Swedish Kidney Cancer Quality Register DataEuropean Urology, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- The genetic basis of kidney cancer: a metabolic diseaseNature Reviews Urology, 2010
- Hyperpolarized 13C Lactate, Pyruvate, and Alanine: Noninvasive Biomarkers for Prostate Cancer Detection and GradingCancer Research, 2008
- Improved Identification of von Hippel-Lindau Gene Alterations in Clear Cell Renal TumorsClinical Cancer Research, 2008